23 deaths in 40 days: Karnataka's heart attack cases fuel COVID-19 vaccine fears, but ICMR finds no link; here's what experts say
Following the incident, the chief minister formed a team of experts, led by Dr. Ravindranath from the Jayadeva Institute, to find out what could be the cause behind the spike in heart attack deaths. On the other hand, another troubling concern is the age group, as most of them were young or middle-aged people.
The Ministry of Health and Family Welfare on Wednesday clarified that no link has been found between the COVID-19 vaccines and the surge in sudden deaths due to heart attacks.
In the past month alone, in just one district of Hassan, more than twenty people have died due to heart attacks. The government is taking this matter very seriously. To identify the exact cause of these series of deaths and to find solutions, a committee of experts has been…
ICMR and AIIMS studies find no link between the COVID-19 vaccine and heart attacks
The health ministry cited extensive studies conducted by the Indian Council of Medical Research (ICMR) and All India Institute of Medical Sciences (AIIMS) on the sudden deaths among adults.
Issuing a statement, the ministry noted, 'Extensive studies by ICMR (Indian Council of Medical Research) and AIIMS on sudden deaths among adults post-COVID have conclusively established no linkage between COVID-19 vaccines and sudden deaths. Studies by ICMR and the National Centre for Disease Control (NCDC) have affirmed that COVID-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects."
Heart attacks, or myocardial infarctions, can occur in individuals who appear healthy, often due to a combination of underlying factors that may not be immediately evident.
In the past month alone, in just one district of Hassan, more than twenty people have died due to heart attacks. The government is taking this matter very seriously. To identify the exact cause of these series of deaths and to find solutions, a committee of experts has been…
Can COVID-19 vaccines trigger heart attacks among young adults?
Research by the Indian Council of Medical Research (ICMR) and AIIMS found no direct link between COVID-19 vaccines and the recent surge in sudden cardiac deaths. 'An analysis of 250 heart attack-related deaths in India ruled out vaccines as a primary cause, consistent with global data from the CDC and WHO. COVID-19 infection itself poses a higher risk of heart complications, with infection-related myocarditis being 5-15 times more common than vaccine-related cases. Vaccination reduces the risk of severe COVID-19, indirectly protecting against heart damage,' says Dr. Basavaraj Utagi, Senior Consultant Cardiology, Fortis Hospital Cunningham Road.
Lifestyle factors play a major role
A major contributing factor is atherosclerosis, a condition in which plaque accumulates in the arteries, leading to narrowing and reduced blood flow to the heart. 'This can occur even in individuals who appear healthy, as underlying issues like high cholesterol or elevated blood pressure may go undetected,' explains Dr. Rahul Gupta, Director of Cardiology at Gleneagles Hospital Parel.
According to Dr. Utagi, 'Lifestyle factors are likely contributing to the spike in cardiac deaths, including psychosocial stress, unhealthy diets, lack of physical activity, smoking, and pollution exposure. Urbanisation has increased access to processed foods, leading to obesity, diabetes, and high cholesterol.'
Rapid urbanisation has exposed a significant proportion of India's population to these risk factors, increasing heart disease risk. 'Chronic stress from fast-paced urban life also elevates cortisol and blood pressure. These factors, rather than vaccines, are likely driving the surge in cardiac problems and deaths,' he adds.
COVID-19 vaccines and heart health
Vaccination remains crucial in preventing severe COVID-19 and its complications. Addressing lifestyle factors and urbanisation-related health risks is essential to mitigating the cardiac disease burden.
'Heart attacks can occur in seemingly healthy people due to various factors such as atherosclerosis, stress, genetics, lifestyle habits, and hidden medical conditions. Staying informed about your health and having regular medical check-ups are key to prevention,' advises Dr. Gupta.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
11 minutes ago
- Indian Express
Closing In On TB
Prime Minister Narendra Modi recently reviewed the National Tuberculosis Elimination Programme (NTEP). His emphasis on public participation and scaling up successful and innovative strategies comes at a critical time. Advances in diagnostics, digital tools, and vaccines are creating opportunities to reshape how we detect, treat, and prevent TB. Progress in recent years is encouraging. According to the WHO's 'Global TB Report 2024', global TB incidence fell by 8.3 per cent between 2015 and 2023. India outpaced this trend, achieving a 17.7 per cent reduction. These gains reflect the focused efforts and commitment of the NTEP. As we look to sustain and accelerate these gains, we must focus on closing the diagnostic gap — the most critical weak link in the TB care cascade. In 2023, an estimated 2.7 million people worldwide who developed TB were not diagnosed or notified. Without diagnosis, timely treatment is impossible, and the chain of transmission continues. Compounding this challenge is the emerging evidence that a significant number of TB patients do not exhibit symptoms. Studies suggest that this early stage of the disease, known as subclinical TB, may account for about 50 per cent of cases in high-burden settings, including India. This is likely a key driver of the ongoing transmission. India's recently concluded 100-day intensified TB-Mukt Bharat Abhiyaan has provided several learnings. By screening vulnerable populations, including those without symptoms, the programme noted that the campaign identified 2.85 lakh asymptomatic TB patients — out of 7.19 lakh diagnosed. These individuals would likely have been missed under conventional, symptom-based screening approaches. By deploying portable chest X-rays, the campaign demonstrated the transformative potential of technology. AI-assisted reading of X-rays can detect lung abnormalities rapidly and accurately, allowing for quick identification of otherwise 'missing' cases. The government's plan to scale up this approach country-wide is encouraging and could serve as a global model. A new generation of point-of-care diagnostic tools is transforming what's possible. Traditional sputum-based tests can be challenging, particularly for children and the elderly. But innovations — such as non-invasive sampling methods like tongue or nasal swabs — can help detect TB earlier and more affordably. The availability of open PCR platforms can be another game-changer — by cutting the cost of testing significantly, these platforms can make high-quality molecular diagnostics accessible across public and private settings. In India, several of these tools are already being piloted, and the Indian Council of Medical Research is playing a key role in facilitating their adoption into routine care. Along with the upgradation of our diagnostic capacity, we must look at reducing mortality due to TB. India has taken important steps to improve supportive care, including the doubling of monthly nutritional support under the Nikshay Poshan Yojana (NPY) — a direct cash transfer scheme that helps patients meet their dietary needs during treatment. This expansion is timely, as undernutrition remains one of the leading risk factors for TB progression. The country is also moving toward differentiated models of TB care, where services are tailored based on a patient's risk profile and severity at diagnosis. This includes early risk stratification, timely referral of severe cases to higher-level facilities, and the provision of more intensive inpatient care where needed. This approach can drive down mortality appreciably and must become a core feature of the TB response. We must prioritise reducing TB deaths to as close to zero as possible in the near future. While these advancements in diagnostics, treatment, and care delivery are crucial, we must not lose sight of the long-term solution — an effective TB vaccine. The experience of developing Covid vaccines demonstrates how global collaboration, streamlined regulatory pathways, and strong public investment can significantly accelerate timelines — an approach that must now be applied to TB vaccine development. India, with its scientific leadership and manufacturing capacity, is uniquely placed to drive the development and equitable deployment of next-generation TB vaccines, just as it did with Covid. An mRNA vaccine is in an early stage of development in India, and others are at various stages of clinical trials. PM Modi's leadership has played a pivotal role in keeping TB elimination high on the national agenda and inspiring other countries to set ambitious goals. With continued political commitment, evidence, data-informed policies and a strong focus on innovation, India can drive transformative change in the global fight against TB. The writer is chairperson, MS Swaminathan Research Foundation and principal advisor, NTEP, Ministry of Health and Family Welfare
Time of India
17 minutes ago
- Time of India
Hassan heart attack death cases: India's top drugmakers rally behind Covid vaccines
Leading drugmakers on Thursday rallied in support of Covid vaccines , using various social media platforms, amid a series of deaths in Karnataka's Hassan district due to heart attacks. Dilip Shanghvi, chairman and managing director at Sun Pharmaceuticals said in a post on LinkedIn, 'The deaths of multiple young individuals in one district of Karnataka due to cardiac ailments are unfortunate. While this appears to be specific to the district, linking it to the Covid-19 vaccine without any scientific evidence is "incorrect and misleading". "India's vaccine approval process is rigorous and science-driven, and we must continue to have confidence in it. The vaccine has been administered to millions across the country. If there were a connection, we would have seen similar incidents in many other places — which is not the case. The State health authorities should thoroughly investigate the situation to determine the cause,' Sanghavi said. Sorting to allay the apprehensions, Pankaj Patel, chairman, Zydus Lifesciences , which also manufactures Covid DNA vaccine, said in a post on X, 'There are other multiple reasons like age, environmental factors, genetics, lifestyle etc, that could be the leading cause of heart attacks in people. Several scientific studies globally and in India have conclusively shown that the risk of heart attack or myocarditis is greater after SARS-CoV-2 infection. #Vaccines save lives.' Appreciating the vaccination programme, Patel said, "the massive vaccination programme in our country during the peak of Covid phase saved millions of people and families. In fact a study published in Lancet estimated that India averted almost 3.4 million deaths due to vaccination in the year 2021," he said. Live Events Satish Reddy, chairman, Dr Reddy's Laboratories, wrote, 'India-made vaccines are by WHO and used worldwide. They helped end polio and fight Covid. At a time when India is seen as a vaccine leader, let's build trust in science, not doubt it. Public health must stay above politics.' A post on X attributed to Samir Mehta, executive chairman, Torrent Pharma said, 'India has earned global recognition as the Pharmacy of the World, supplying safe and effective vaccines to over 90 countries…Let's not allow misinformation to erode trust in science or the integrity of India's healthcare ecosystem.' Responding to rising concerns over the sudden deaths of more than 20 people in Hassan district, the Karnataka health department formed an expert committee to probe a possible link to Covid vaccines. However, support came pouring in for Covid vaccines. The Indian Vaccine Manufacturers Association said Covid-19 vaccines were developed and manufactured in the country with the highest safety and quality standards. Assuring about the safety of these vaccines, Dr/ G.V.J.A. Harshavardhan, director general at the association said the approvals were based on extensive evaluation in preclinical studies and human clinical trials with positive results on safety, efficacy, and immunogenicity of the vaccines. 'Patient safety and product quality are always prioritised during the vaccine development and its manufacture,' he said in a statement. He said prior to releasing the vaccines, they were tested extensively for safety by the manufacturers and are also provided batch release certification by the Central Drugs Laboratory (CDL) of the Ministry of Health and Family Welfare. Sudarshan Jain, secretary general, Indian Pharmaceutical Alliance (IPA) said during the pandemic, vaccines played a crucial role, and India consistently supplied medicines and vaccines across the world. "These vaccines have been well documented and rigorously tested as per regulatory processes. Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally".
Mint
an hour ago
- Mint
AIIMS says no link between covid jabs and sudden deaths among young adults
Doctors at Delhi's All India Institute of Medical Sciences (AIIMS-Delhi) have refuted claims linking Covid-19 vaccines to sudden deaths in young adults in the country. This comes in the backdrop of recent claims by Karnataka Chief Minister Siddaramaiah stating that covid vaccines were linked to sudden deaths due to cardiac arrest among young adults in the state's Hassan district. The country's premier medical institution announced that its studies have found no such connection, instead attributing these tragic incidents primarily to lifestyle factors such as smoking, high blood pressure, and stress. Senior AIIMS doctors emphasized the crucial role these vaccines played in saving lives during the pandemic, noting that the studies are ongoing to determine the causes of sudden unexplained deaths. Researchers at AIIMS's pathology department are currently undertaking genomic studies to find the unexplained causes of death in approximately 25% of cases involving young individuals, where no apparent cause was initially identified. The pharmaceutical industry has also vouched for vaccine safety and debunked doubts over efficacy. Dr. Abhishek Yadav, additional professor in the department of forensic medicine at AIIMS, detailed two studies conducted by his department. A retrospective analysis from 2018 to 2022, comparing pre- and post-Covid data, found "no surge in the sudden cardiac deaths in the cases which were reported in the department". A second, ongoing study, initiated in 2023 in collaboration with the Indian Council of Medical Research (ICMR) and slated to continue for another year and a half, aims to gather more samples for scientifically validated results. This study has so far examined approximately 230 death cases, collecting family history, performing genomic and DNA level studies, and utilizing virtual autopsies. Dr. Yadav stated that this second study has also 'not found any link between covid vaccine and sudden deaths.' The research categorized cases into two age groups: 18-45 years and 45-65 years. Dr. Yadav said that coronary artery disease was identified as the most common historical factor, with over 50% of these cases linked to lifestyle factors and substance abuse, such as alcohol and smoking. The pathology department of AIIMS is continuing genomic studies on the remaining 25% of unexplained cases. Dr. Sudheer Arava, a professor in the department of pathology at AIIMS, explained that the study of 230 young individuals brought to the forensic department found heart attack to be the most common cause of death (50%), often linked to lifestyle risk indicators like high blood pressure, cholesterol, stress, and obesity. 'In 25% of cases, no identifiable cause of death was determined, and researchers are exploring potential molecular alterations. An interim report submitted to the ICMR indicates that nearly 50% of the deaths studied were due to heart attacks, with further research ongoing.' Dr. Sanjay Rai, professor at the department of community medicine at AIIMS, stated that the Covishield vaccine (developed by Oxford–AstraZeneca) showed an efficacy of 62.1%. He highlighted that various regulatory authorities have approved 37 different Covid-19 vaccines, with the World Health Organization (WHO) approving approximately 12, utilizing diverse technologies. For instance, Bharat Biotech's Covaxin uses a traditional technology, while Covishield and Russian Sputnik V are based on an adenovirus vector. Globally, over 13 billion vaccine doses have been administered, with countries like the United States completing fourth doses. The WHO now recommends vaccination for everyone aged six months and above, particularly with vaccines effective against newer variants. Dr. Karan Madan, associate professor in the department of pulmonary medicine, affirmed that Covid-19 vaccines were "highly effective and instrumental in lowering mortality rates during the pandemic". He emphasized their role as the "sole possible measure to save lives" at the time, providing "immense advantages" in preventing excess deaths. Dr. Madan also referenced a study on sudden cardiac deaths that found "no clear association" with vaccine usage. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), underscored India's role as a knowledge-driven sector, accounting for 60% of global vaccine production. He stated that Covid vaccines were "well documented and rigorously tested as per regulatory processes," warning that "misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally". The Indian Vaccine Manufacturers Association also said that all Covid-19 vaccines in India received Emergency Use Authorization based on extensive preclinical and human clinical trial evaluations, showing positive results for safety, efficacy, and immunogenicity. Covid infections have been on a declining trend after showing a steady increase in the past few weeks. On Thursday, the country's active caseload dropped to 1,290 from 1,691 cases, with no deaths reported in the last 24 hours. The total number of Covid-19-related deaths this year stands at 146. The current spread is linked to Omicron sub-variants NB.1.8.1 and LF.7.
